Vetter and Rentschler Biopharma Strengthen Strategic Alliance

April 29, 2021
BioPharm International Editors

Vetter and Rentschler Biopharma have announced the strengthening of their strategic alliance.

Vetter and Rentschler Biopharma, both global contract manufacturing and development organizations (CDMOs), have announced the strengthening of their strategic alliance in an April 28, 2021 press release.

Key steps forward in the CDMOs relationship include the establishment of a framework for their alliance and the setting up of a governance structure. Additionally, the companies have implemented guidelines for their joint approach across functions. The companies have started their first joint client projects while simultaneously working closely on existing projects and related topics, it was revealed in the press release.

Initiated in mid-2020, the collaboration was aimed at the creation of long-term value through the alignment of manufacturing approaches, which can improve time-to-market. The established framework comprises an overall collaboration agreement, regulating the intended contributions of both parties.

Further operational agreements and guidelines between various departments, such as quality, development service, and logistics have also been implemented. These agreements provide key standards for joint approaches as well as core inputs and processes across both organizations to align interfaces and optimize services. The alignment of the departments also includes the CDMOs’ global business development teams.

“The formation of the mutual agreements and alignment on a client approach were foundational steps that both Vetter and Rentschler Biopharma identified early in our exploration of this strategic alliance,” said Peter Soelkner, Vetter managing director, in the press release. “We look forward to the new progress that this step will facilitate.”

“We are very interested to see how the experience gained in these initial projects will further enhance our strategic alliance,” added Frank Mathias, CEO of Rentschler Biopharma, in the press release. “These client engagements will provide valuable insights for our teams to leverage in refining the alignment of our processes and approaches.”

Source: Vetter